Keywords: atherogenics, starts, ph, ii, ra, trial, agix-4207

AtheroGenics starts Ph II RA trial for AGIX-4207

Article | 27 October 2003

Print This

Atherogenics of the USA has commenced a Phase II trial of itsAGIX-4207 in patients with rheumatoid arthritis. The study, designated ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in